FCGR2A and neoplasm: Its anti-tumor actions include halting cell proliferation by upregulating p21/WAF-1, enhancing p53 expression, and inhibiting BAFF and MMP9, alongside activating FcgR and recognizing tumor cell oligosaccharides through natural antibodies in the plasma (11, 13, 14, 17–19).